November 7, 2016
Vertex's Phase 3 cystic fibrosis drug study shows improvement
Vertex Pharmaceuticals Incorporated today announced the results of a Phase 3 study of Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis…
Pharmaceuticals, Biotechnology and Life Sciences
Vertex Pharmaceuticals Incorporated today announced the results of a Phase 3 study of Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis…
The European Commission has approved expansion of the indication for Vertex Pharmaceuticals’ Kalydeco, to include children ages 2-5 with cystic fibrosis…